Elucidation of the genetic and molecular background of VDR in the pathophysiology of NAFLD will provide new therapeutic targets for this disease through the development of VDR agonists, which already showed promising results in vivo. The gene discussed is VDR; the disease is metabolic dysfunction-associated steatotic liver disease.